Bilateral Radical Orchidectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bilateral radical orchidectomy (also written as bilateral orchiectomy) is the surgical removal of both testicles. The term 'radical' in this context — particularly when referring to testicular cancer — implies removal of the entire testicle and its covering (tunica vaginalis) via an inguinal (groin) approach, avoiding scrotal incision that could compromise lymphatic drainage patterns relevant to cancer staging. When both testicles are removed, the procedure results in surgical castration — permanent elimination of testicular testosterone production.

The most common indication for bilateral orchidectomy is androgen deprivation therapy (ADT) for advanced prostate cancer. Prostate cancer cells are predominantly androgen-sensitive, meaning testosterone drives their growth. Removing the primary source of testosterone — the testes, which produce 90–95% of circulating testosterone — suppresses tumour growth and is a cornerstone of treatment for metastatic or locally advanced prostate cancer. Castrate testosterone levels (below 50 ng/dL, ideally below 20 ng/dL) are achieved within hours of surgery, significantly faster than medical castration with LHRH analogues (which take 2–4 weeks and require additional androgen receptor blockade to prevent initial testosterone 'flare').

Other indications include bilateral germ cell tumours of the testes (rare), gender-affirming surgery in transgender women, and rare hormonal or autoimmune conditions. The procedure is performed under general, spinal, or local anaesthesia and is completed within 30–60 minutes as a day surgery or overnight procedure. Recovery is rapid, typically 2–4 weeks, but the hormonal consequences are immediate and lifelong.

Bilateral radical orchidectomy is performed for the following conditions:

• Metastatic or locally advanced prostate cancer: The most common indication. Bilateral orchidectomy achieves permanent androgen deprivation in patients with hormone-sensitive prostate cancer who have metastatic disease, locally advanced disease (T3/T4), or biochemical recurrence after primary therapy where sustained ADT is planned. It is equally effective to, less expensive than, and avoids the compliance issues of long-term LHRH analogue injection therapy.
• Bilateral testicular germ cell tumours: Rare scenario where synchronous or metachronous germ cell tumours affect both testicles (accounts for approximately 1–2% of testicular cancer presentations). Bilateral orchidectomy may be required when testis-sparing surgery is not feasible due to tumour size, location, or extent.
• Testicular cancer with prior contralateral orchidectomy: If a patient has already undergone unilateral radical orchidectomy for testicular cancer and develops a second tumour in the remaining testicle requiring complete removal, the result is functional bilateral orchidectomy.
• Gender-affirming surgery (transgender women): Bilateral orchidectomy is a component of feminising genital surgery (vaginoplasty), eliminating endogenous testosterone production and enabling reduction or elimination of feminising hormone therapy doses post-operatively. It may also be performed as a standalone procedure ('simple orchiectomy') without full vaginoplasty.
• Severe, refractory paraphilias (rare, legal jurisdiction-specific): In some jurisdictions, voluntary surgical castration has been used as treatment for certain severe paraphilic disorders under strict ethical and legal oversight; this is exceedingly rare and highly regulated.

Patient selection for bilateral orchidectomy depends on the underlying indication:

Prostate Cancer

• Confirmed androgen-sensitive prostate cancer at a stage requiring sustained ADT (metastatic, locally advanced, or biochemical recurrence with high-risk features).
• Patient preference for permanent, surgical ADT over ongoing injections or oral medication. This is often preferred by patients in low-resource settings, those with poor medication adherence, or those prioritising a one-time procedure over long-term treatment.
• Adequate performance status for short operative procedure (most patients are eligible; this is a relatively minor operation).
• Informed understanding of permanent, irreversible nature of the procedure.

Testicular Cancer

• Histologically confirmed bilateral germ cell tumours on imaging and/or biopsy where testis-sparing surgery (partial orchidectomy) is not oncologically feasible.
• Pre-operative assessment of tumour markers (AFP, beta-hCG, LDH) and staging CT for surgical planning.

Gender-Affirming Care

• Meets established criteria for gender dysphoria / gender incongruence as defined by WPATH Standards of Care v8 (or national equivalent).
• Has undergone adequate duration of gender-affirming hormone therapy (typically 12 months of oestrogen therapy prior to surgical eligibility, though this requirement varies by centre and national guidelines).
• Supported by mental health professional assessment where required by the patient's care pathway.

The technical approach to bilateral orchidectomy varies slightly depending on the indication:

Radical Inguinal Bilateral Orchidectomy (Testicular Cancer)

Each testicle is removed via a separate inguinal incision (groin crease), not through the scrotum. The spermatic cord is ligated and divided at the level of the internal inguinal ring to achieve a high ligation that removes the entire lymphovascular pedicle without disrupting inguinal and scrotal lymphatics (which drain to the inguinal nodes rather than the retroperitoneal nodes where testicular cancer spreads). Scrotal incision is strictly avoided in testicular cancer to prevent inadvertent alteration of lymphatic drainage, which would complicate subsequent lymph node assessment and treatment. Intraoperative frozen section biopsy may be performed.

Simple Bilateral Orchidectomy (Prostate Cancer / Androgen Deprivation)

A single midline or bilateral scrotal incision provides access to both testicles. Subcapsular orchidectomy — removing the testicular parenchyma (tissue contents) while leaving the tunica albuginea shell in place — maintains scrotal volume and appearance and is widely used in prostate cancer patients to preserve body image without altering cosmetic appearance significantly. Total orchidectomy (removing the entire testicle including its covering) may also be performed. Both approaches achieve equivalent testosterone suppression.

Testicular Prosthesis Insertion

A silicone testicular prosthesis can be placed into the scrotum at the time of orchidectomy or as a delayed procedure. Available in small, medium, and large sizes; filled with saline or cohesive silicone gel. The implant is positioned within the scrotal sac and secured with a suture to prevent rotation. Discussion pre-operatively allows the patient to make an informed choice about prosthesis insertion.

Anaesthesia Options

General anaesthesia is standard, but spinal (epidural) or local anaesthesia with sedation are suitable for many patients, particularly those with cardiorespiratory comorbidity, as the procedure is brief and the operative site is limited to the inguinoscrotal region.

• Immediate and permanent testosterone suppression: Castrate testosterone levels (<50 ng/dL) are achieved within 3–12 hours of surgery — the most rapid form of androgen deprivation available, with no risk of testosterone 'flare' seen with LHRH agonists.
• No ongoing medication compliance required: Unlike LHRH agonists or antagonists requiring monthly, quarterly, or 6-monthly injections or daily oral pills, surgical castration is a one-time procedure with permanent effect. This eliminates treatment burden and adherence concerns.
• Cost-effective long-term: A single procedure versus years of expensive LHRH analogue injections (USD 3,000–6,000/year in the US) makes bilateral orchidectomy economically attractive for patients requiring lifelong ADT.
• Prostate cancer tumour response: Androgen deprivation produces objective responses (PSA decline, tumour regression, symptom improvement) in 80–90% of patients with hormone-sensitive prostate cancer, improving quality of life and extending survival.
• Rapid symptom relief: In patients with bone pain, urinary obstruction, or haematuria from advanced prostate cancer, testosterone suppression can produce significant symptom improvement within days to weeks.
• No injection-site complications: Avoids the bruising, injection pain, and rare adverse reactions (anaphylaxis, injection-site granuloma) associated with depot LHRH analogue formulations.
• Simplicity and reliability: A straightforward, reproducible operative procedure with predictable hormonal outcomes.

Bilateral orchidectomy carries both surgical and hormonal risks:

Surgical Complications

• Haematoma (1–3%): Scrotal or inguinal haematoma formation post-operatively; most resolve conservatively, occasional cases require surgical drainage.
• Wound infection (<2%): Managed with antibiotics; rarely requires re-exploration.
• Prosthesis complications (if inserted): Extrusion (<1%), infection, displacement, or rotation of the testicular prosthesis.
• Chronic wound pain: Scar sensitivity or neuralgia at the operative site; uncommon.
• Damage to vas deferens or epididymis: Not oncologically significant after bilateral orchidectomy for ADT.

Hormonal / Systemic Consequences

• Hot flushes (50–80%): The most common and often most troubling symptom of castration; managed with low-dose medroxyprogesterone, gabapentin, venlafaxine, or acupuncture.
• Fatigue and reduced energy levels.
• Loss of libido and erectile dysfunction.
• Loss of muscle mass and increased body fat.
• Osteoporosis: Testosterone is essential for bone density maintenance. Long-term castration (particularly beyond 12 months) significantly increases fracture risk. Bisphosphonates (zoledronic acid) or denosumab are recommended for bone protection. Weight-bearing exercise and calcium/vitamin D supplementation are important adjuncts.
• Anaemia: Testosterone supports erythropoiesis; surgical castration can cause mild normochromic normocytic anaemia.
• Cognitive effects: Some evidence suggests long-term ADT is associated with increased risk of cognitive impairment and dementia; active research area.
• Cardiovascular risk: ADT is associated with increased risk of metabolic syndrome, insulin resistance, and potentially adverse cardiovascular events; monitoring and management of metabolic risk factors is important.
• Psychological impact: Altered body image, loss of masculinity perceptions, depression, and relationship effects are common concerns requiring psychological support.
• Irreversibility: Unlike medical castration, surgical castration cannot be reversed. This must be clearly understood and consented to before the procedure.

Recovery from the operative procedure itself is rapid; the ongoing management of hormonal consequences requires long-term follow-up:

Immediate Recovery (Days 1–7)

The procedure is typically performed as day surgery or with one overnight stay. Scrotal support (supportive underwear or a scrotal support garment) is recommended for 2 weeks to reduce swelling and haematoma risk. Mild analgesia (paracetamol, NSAIDs) is adequate for most patients. Strenuous physical activity and heavy lifting are avoided for 2 weeks. Sexual activity can typically resume after 2–4 weeks once the wound has healed.

Hormonal Confirmation

Serum testosterone is measured at 1–4 weeks post-operatively to confirm castrate levels have been achieved (target: <50 ng/dL; ideally <20 ng/dL). Failure to achieve castrate levels suggests incomplete tissue removal (rare) and warrants re-evaluation.

Prostate Cancer Monitoring

PSA measurement at 3 and 6 months, then 6-monthly, assesses tumour response to androgen deprivation. Rising PSA despite castrate testosterone indicates castration-resistant prostate cancer (CRPC) — a major disease milestone requiring additional systemic therapy (enzalutamide, abiraterone, docetaxel, or newer agents).

Bone Health

Baseline DEXA (dual-energy X-ray absorptiometry) bone density scan is recommended before or at the time of orchidectomy. Oral bisphosphonate therapy, calcium (1,000–1,200 mg/day), vitamin D (800–1,000 IU/day), and supervised weight-bearing exercise are initiated to mitigate osteoporosis risk.

Metabolic Monitoring

Fasting glucose, HbA1c, lipid profile, full blood count, and body weight should be checked at 6 and 12 months, then annually, to screen for metabolic complications of long-term androgen deprivation.

Bilateral orchidectomy is among the less expensive major surgical procedures; its primary economic advantage over medical castration becomes apparent over time:

• Operative cost: In the US, total costs (surgeon, facility, anaesthesia) range from USD 3,000–8,000 as a day-case procedure. In the UK, NHS rates are substantially subsidised; private rates range GBP 1,500–4,000. In India, Thailand, or Turkey, packages at internationally accredited facilities range from USD 500–2,500.
• Comparison with medical castration: Monthly LHRH agonist injections (e.g., leuprolide, goserelin) cost USD 3,000–10,000 per year in the US, depending on depot duration (monthly vs. 3-monthly vs. 6-monthly). Over a 5-year period, medical castration costs USD 15,000–50,000 in drug costs alone — far exceeding the one-time cost of surgical orchidectomy. In resource-limited settings, this cost differential is decisive in favour of surgery.
• Prosthesis: Testicular prostheses add USD 500–1,500 per implant to procedural costs in the US; similar ranges internationally. This is optional and chosen based on patient preference.
• Ongoing hormonal management: Bone protection therapy (zoledronic acid infusions: USD 800–2,000/year; denosumab injections: USD 1,200–2,000/year), monitoring visits, and psychosocial support represent ongoing costs that are common to both surgical and medical ADT pathways.
• Insurance coverage: Bilateral orchidectomy for prostate cancer treatment is generally covered by major insurers as a standard-of-care procedure. Gender-affirming orchidectomy coverage varies by insurer and jurisdiction; coverage has expanded substantially in many countries following updated transgender health guidelines.

For each indication, the following alternatives should be discussed:

For Androgen Deprivation in Prostate Cancer

• LHRH agonists (most common medical alternative): Leuprolide (Lupron), goserelin (Zoladex), triptorelin (Decapeptyl), and buserelin suppress pituitary LH release, reducing testicular testosterone production. Administered as monthly, 3-monthly, or 6-monthly subcutaneous or intramuscular depot injections. Reversible and equivalent to surgical castration in tumour control. Require concomitant anti-androgen for the first 2–4 weeks to prevent testosterone 'flare'.
• LHRH antagonists (GnRH antagonists): Degarelix (Firmagon) and relugolix (Orgovyx, oral) achieve castrate testosterone levels within 24–72 hours without testosterone flare. Relugolix (oral, once-daily) showed superior cardiovascular safety over leuprolide in the HERO trial. These are increasingly preferred over agonists in men with cardiovascular disease.
• Androgen receptor inhibitors: Enzalutamide, apalutamide, and darolutamide block androgen receptor signalling. Used in combination with ADT (or as monotherapy in some trials) for castration-resistant or high-risk hormone-sensitive disease.
• Combined androgen blockade (CAB): LHRH analogue plus first-generation anti-androgen (bicalutamide, flutamide); provides blockade of both testicular and adrenal androgens. Small survival benefit over monotherapy ADT in metastatic disease.

For Bilateral Testicular Cancer

• Testis-sparing surgery (partial orchidectomy): Feasible for small, well-defined tumours (typically <2 cm) with a solitary remaining testis. Requires intraoperative ultrasound guidance and frozen section biopsy to confirm negative margins. Testosterone replacement will likely be needed if the remaining testicular parenchyma is insufficient after excision.
• Chemotherapy (BEP regimen): For metastatic germ cell tumours, bleomycin + etoposide + cisplatin (BEP) chemotherapy achieves cure in 80–90% of disseminated disease — remarkably high for a metastatic solid tumour. Orchidectomy is still performed for the primary tumour even when chemotherapy controls metastatic disease.

For Gender-Affirming Care

• Long-term oestrogen hormone therapy without surgery: Gender-affirming hormone therapy (GAHT) with oestradiol, with or without anti-androgens (spironolactone, cyproterone acetate, or GnRH analogues), suppresses testosterone and feminises appearance without surgery. Many transgender women choose hormone therapy alone without orchidectomy.
• GnRH analogue puberty suppression: In adolescents, GnRH analogues reversibly pause puberty and testosterone production, allowing time for gender exploration without permanent intervention.